Itulazax

Betula verrucosa, the active ingredient in Itulazax, is an allergen extract presented as a sublingual formulation for sublingual use. It is employed to treat allergic rhinitis caused by birch pollen in patients with documented sensitivity.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Itulazax is an allergen extract used in allergy immunotherapy for patients sensitized to birch pollen. - Allergic rhinitis (birch pollen): reduces nasal congestion, sneezing, and itching by inducing tolerance to the birch allergen. - Seasonal allergic conjunctivitis (birch pollen): alleviates eye redness and itching through the same immunological mechanism. - Preventive seasonal allergy management: helps maintain symptom control throughout the birch pollen season.

Side effects are generally mild and related to local exposure of the oral mucosa.

Common Side Effects: - Oral itching or tingling: transient sensation in the mouth after administration. - Mild throat irritation: slight discomfort that resolves without intervention. - Taste disturbance: temporary alteration in taste perception.

Serious or Rare Side Effects: - Anaphylaxis: severe, systemic allergic reaction requiring immediate medical attention. - Angioedema of the lips or tongue: swelling that may compromise airway. - Respiratory distress: difficulty breathing indicating a systemic response. - Urticaria: widespread hives occurring after dosing.

Patients should be evaluated for allergy severity and monitored during initial dosing. - Initial dosing under medical supervision: observe for adverse reactions during the first administration. - Contraindicated in individuals with a history of severe anaphylaxis to birch pollen. - Caution in uncontrolled asthma: may increase risk of bronchospasm. - Avoid concurrent use of other allergen extracts without physician guidance. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid): - Concurrent use of ACE inhibitors in patients with a history of angioedema: may exacerbate swelling. - Beta‑blockers during immunotherapy: can mask early signs of anaphylaxis.

Moderate Interactions (Monitor Closely): - Other sublingual immunotherapy products: may increase cumulative allergen exposure. - Antihistamines taken shortly before dosing: may reduce local reaction but do not affect efficacy. - Immunosuppressive agents: could alter the immune response to the allergen extract.